A fully humanized IgG1 antibody–drug conjugate targeting B7‑H3 (CD276). Upon binding to B7‑H3 on tumor cells, it is internalized and releases a cytotoxic payload; as an IgG1 it may also mediate Fc‑effector functions. Evaluated as IV 8 mg/kg Q3W monotherapy in mCRPC and other advanced solid tumors.
Fully human IgG1 ADC targeting B7-H3 (CD276). Upon binding to B7-H3 on tumor cells, the complex is internalized and releases a topoisomerase inhibitor payload that inhibits DNA topoisomerase activity, blocking DNA replication and causing cell-cycle arrest and apoptosis of B7-H3–expressing cells; the IgG1 may also mediate Fc-effector functions (e.g., ADCC/ADCP).
ADC binds B7-H3, is internalized, and releases a topoisomerase inhibitor that blocks DNA replication causing cell-cycle arrest and apoptosis; IgG1 Fc can also trigger ADCC/ADCP against B7-H3–expressing cells.
Allogeneic CD19-directed CAR-γδ T cell therapy; γδ T cells engineered with an FMC63-based CD19 CAR to mediate largely MHC-independent cytotoxicity and cytokine release against CD19+ B-ALL.
Allogeneic γδ T cells engineered to express a CD19-specific CAR (FMC63 scFv) bind CD19 on malignant B cells and, upon CAR signaling, execute largely MHC-independent cytotoxicity via perforin/granzyme release and cytokine secretion, leading to targeted lysis of CD19+ leukemia cells.
CD19-specific CAR-γδ T cells bind CD19 on target cells and, upon CAR signaling, induce MHC-independent killing via perforin/granzyme-mediated cytolysis and cytokine release.
Anti-CD20 monoclonal antibody that depletes CD20-positive B cells via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and apoptosis.
Chimeric anti-CD20 monoclonal antibody that binds CD20 on B lymphocytes and depletes CD20+ cells via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and induction of apoptosis.
Binds CD20 on B cells and triggers antibody-dependent cellular cytotoxicity via FcγR-expressing effector cells, complement-dependent cytotoxicity/lysis, and can induce apoptosis.
Subcutaneous CD20×CD3 bispecific T‑cell–engaging monoclonal antibody that redirects CD3+ T cells to kill CD20+ malignant B cells.
Humanized bispecific monoclonal antibody that binds CD3 on T cells and CD20 on B cells, cross-linking T cells to malignant B cells to form an immune synapse, activate T cells, and induce targeted T‑cell–mediated cytotoxicity against CD20+ tumor cells.
Mosunetuzumab bridges CD20 on B cells and CD3 on T cells, forming an immune synapse and activating T cells to kill CD20+ cells via perforin/granzyme-mediated cytotoxicity.
A bispecific T-cell engager antibody targeting BCMA and CD3 that redirects T cells to kill BCMA-positive myeloma cells via immune synapse formation and cytokine-mediated cytotoxicity.
Bispecific antibody that simultaneously binds BCMA on myeloma cells and CD3 on T cells, forming an immune synapse that redirects T-cell cytotoxicity and cytokine release to kill BCMA-positive plasma cells.
The bispecific binds BCMA on target cells and CD3 on T cells, forming an immune synapse that activates T-cell cytotoxicity (perforin/granzyme release and cytokine-mediated killing) to lyse BCMA-positive cells.